Holen Sie sich die Stockscreener-App
1.19
0.00%
0.00
Handel nachbörslich:
1.19
Schlusskurs vom Vortag:
$1.19
Offen:
$1.2
24-Stunden-Volumen:
47,419
Relative Volume:
0.20
Marktkapitalisierung:
$26.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.29M
KGV:
-1.0085
EPS:
-1.18
Netto-Cashflow:
$-17.12M
1W Leistung:
+3.48%
1M Leistung:
-4.03%
6M Leistung:
-17.36%
1J Leistung:
-57.35%
1-Tages-Spanne:
$1.14
$1.2096
1-Wochen-Bereich:
$1.12
$1.2096
52-Wochen-Spanne:
$0.8101
$4.59
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Firmenname
Enlivex Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ENLV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.19 | 26.17M | 0 | -22.29M | -17.12M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.73 | 113.24B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.64 | 76.33B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
652.19 | 39.00B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.54 | 35.54B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.12 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-02 | Bestätigt | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Aktie (ENLV) Neueste Nachrichten
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Enlivex CEO to Showcase Breakthrough Allocetra Cell Therapy on Bloomberg TV Special Feature - StockTitan
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance
Hoth’s phase IIa derma data in cancer patients propels its stock - BioWorld Online
Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 6% – Still a Buy? - Defense World
Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial - Yahoo Finance
Enlivex Receives Regulatory Authorization for the Initiation of A Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - Marketscreener.com
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times
Enlivex's Allocetra Trial Shows 50% Pain Reduction in Knee Osteoarthritis Study - StockTitan
Enlivex Therapeutics Faces Financial Challenges Amid Losses - TipRanks
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3 - AccessWire
Enlivex to Showcase Promising Allocetra™ Cell Therapy Data in Exclusive Investor Webinar | ENLV Stock News - StockTitan
Enlivex Therapeutics to Invest in Bitcoin as Part of Cash Management Strategy - Binance
Enlivex Therapeutics : Adopts Bitcoin Treasury Reserve Strategy Form 6 K - Marketscreener.com
Enlivex Therapeutics : X Adopts Bitcoin Treasury Reserve Strateg - Marketscreener.com
Enlivex Adopts Bitcoin Treasury Reserve Strategy - GlobeNewswire
Enlivex Therapeutics to Buy Up to $1M in Bitcoin as Treasury Reserve Asset | ENLV Stock News - StockTitan
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Growth in Short Interest - Defense World
Armistice Capital, LLC Expands Stake in Enlivex Therapeutics Ltd - GuruFocus.com
Enlivex Announces the Dosing of the First Patient in a - GlobeNewswire
Enlivex Launches Phase I Trial for Novel Psoriatic Arthritis Treatment Allocetra™ | ENLV Stock News - StockTitan
Enlivex stock hits 52-week low at $1.15 amid market challenges - Investing.com Canada
Enlivex Announces the Enrollment and Dosing of the First 10 - GlobeNewswire
Enlivex's Allocetra Advances: Phase II Trial Launches for Knee Osteoarthritis Treatment | ENLV Stock News - StockTitan
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know - MSN
Enlivex Therapeutics Reschedules Annual Shareholders Meeting - TipRanks
Enlivex Receives Notice of Allowance for Japanese Patent - GlobeNewswire
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis - StockTitan
New Strong Buy Stocks for October 23rd - MSN
New Strong Buy Stocks For October 23rd - Barchart
Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA By Investing.com - Investing.com South Africa
Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA - Investing.com Australia
EF Hutton maintains price target on Enlivex after trial advancement By Investing.com - Investing.com Australia
Enlivex Advances Knee Osteoarthritis Treatment Trial - TipRanks
Enlivex Receives Authorization from the Danish Medicines - GlobeNewswire
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis - StockTitan
ENLVEnlivex Therapeutics Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Enlivex Progresses to Phase II for Knee Arthritis Treatment - TipRanks
Enlivex Announces Positive DSMB Recommendation to Initiate - GlobeNewswire
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis - StockTitan
India News | ⚡Kolkata-Based Company Ellenbarrie Industrial Gases Files IPO Papers - LatestLY
Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com Canada
Enliven Therapeutics Announces Details Regarding the - GlobeNewswire
Ellenbarrie Industrial Gases Files For IPO To Raise Rs 400 Crore - NDTV Profit
Enmy & The Cure - RAMzine
ENLV’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation - Simply Wall St
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy - MSN
Enlivex Announces 2024 Shareholder Meeting - TipRanks
Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at HC Wainwright - Defense World
Finanzdaten der Enlivex Therapeutics Ltd-Aktie (ENLV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):